[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,736,205
  • Shares Outstanding, K 193,284
  • Annual Sales, $ 3,221 M
  • Annual Income, $ 348,900 K
  • EBIT $ 334 M
  • EBITDA $ 409 M
  • 60-Month Beta 0.24
  • Price/Sales 3.60
  • Price/Cash Flow 21.03
  • Price/Book 1.87

Options Overview Details

View History
  • Implied Volatility 55.09% (+2.36%)
  • Historical Volatility 21.72%
  • IV Percentile 99%
  • IV Rank 98.67%
  • IV High 55.46% on 02/23/26
  • IV Low 27.50% on 01/15/26
  • Expected Move (DTE 16) 2.70 (4.49%)
  • Put/Call Vol Ratio 1.59
  • Today's Volume 311
  • Volume Avg (30-Day) 695
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 31,485
  • Open Int (30-Day) 32,972
  • Expected Range 57.52 to 62.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.79
  • Number of Estimates 6
  • High Estimate $0.99
  • Low Estimate $0.62
  • Prior Year $1.25
  • Growth Rate Est. (year over year) -36.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.42 +4.58%
on 07/23/26
63.05 -4.76%
on 07/28/26
+1.06 (+1.80%)
since 07/02/26
3-Month
49.26 +21.91%
on 05/18/26
63.05 -4.76%
on 07/28/26
+6.81 (+12.79%)
since 05/05/26
52-Week
49.26 +21.91%
on 05/18/26
66.28 -9.39%
on 02/24/26
-1.88 (-3.04%)
since 08/05/25

Most Recent Stories

More News
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect

BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect

BMRN : 60.25 (-0.77%)
1 Profitable Stock with Impressive Fundamentals and 2 We Turn Down

1 Profitable Stock with Impressive Fundamentals and 2 We Turn Down

R : 266.87 (-0.72%)
BMRN : 60.25 (-0.77%)
EME : 826.26 (+0.78%)
BioMarin Reports While Analysts Wonder What Changed Between Upgrades and Downgrades

Barchart Research What to Expect from BMRN Earnings BMRN Generated July 31, 2026 Current Price $60.02 EPS Estimate $$0.79 Consensus Rating Moderate Buy Average Move 3.39% BioMarin Reports While Analysts...

BMRN : 60.25 (-0.77%)
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET

SAN RAFAEL, Calif. , July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...

BMRN : 60.25 (-0.77%)
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome

ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition

BMRN : 60.25 (-0.77%)
2 Reasons to Avoid BMRN and 1 Stock to Buy Instead

2 Reasons to Avoid BMRN and 1 Stock to Buy Instead

BMRN : 60.25 (-0.77%)
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm...

BMRN : 60.25 (-0.77%)
1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid

1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid

PAR : 17.53 (+0.57%)
RPC : 9.08 (+0.44%)
BMRN : 60.25 (-0.77%)
2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore

2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore

FIX : 1,775.19 (-0.04%)
BMRN : 60.25 (-0.77%)
DOCU : 57.21 (-0.57%)
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off

2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off

BSX : 47.27 (-3.71%)
BMRN : 60.25 (-0.77%)
ICUI : 167.08 (-2.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 62.76
2nd Resistance Point 61.79
1st Resistance Point 61.26
Last Price 60.25
1st Support Level 59.76
2nd Support Level 58.79
3rd Support Level 58.26

See More

52-Week High 66.28
Last Price 60.25
Fibonacci 61.8% 59.77
Fibonacci 50% 57.77
Fibonacci 38.2% 55.76
52-Week Low 49.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.